Oncoceutics Inc., has partnered with NIH with matters related to its imipridone family of anti-cancer compounds. ONC206 has been studied extensively for several years in models of central nervous system cancers, including high grade gliomas as evaluated by the laboratory of Mark Gilbert, chief of the Neuro-Oncology Branch, Center for Cancer Research, NCI.
Elicio Therapeutics announced the appointment of Robert Connelly as CEO. Elicio is developing precision vaccines, immuno-stimulators, and cellular therapies based on the work of Darrell Irvine, professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
FDA approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide, for the initial treatment of adults with extensive-stage small cell lung cancer.
Strata Oncology announced the launch of version 3.0 of StrataNGS, its pan-cancer assay for solid tumors.
Oncoceutics Inc., announces the expansion of its diverse collaborations across the NIH involving its imipridone family of anti-cancer compounds.
FDA has issued warning letters to two breast implant manufacturers for failure to comply with their requirements, under their premarket approval orders, to conduct post-approval studies to assess the long-term safety and risks of their silicone gel-filled breast implants.
European Commission has approved Keytruda in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adults with metastatic squamous non-small cell lung cancer.
FDA has granted accelerated approval to Tecentriq (atezolizumab) plus chemotherapy (Abraxane [nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, as determined by an FDA-approved test.
FDA has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor receptor–2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Myriad Genetics Inc. said the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination for the myPath Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology.